<DOC>
	<DOCNO>NCT00444925</DOCNO>
	<brief_summary>To evaluate efficacy safety fesoterodine comparison tolterodine placebo overactive bladder</brief_summary>
	<brief_title>Clinical Trial Evaluate Efficacy Safety Fesoterodine Comparison Tolterodine Overactive Bladder ( OAB )</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<mesh_term>Fesoterodine</mesh_term>
	<criteria>Adult overactive bladder ( OAB ) patient present OAB symptom , include urinary frequency &gt; = 8 per day urgency urinary incontinence &gt; =1 per day Patients condition would contraindicate fesoterodine use , e.g , hypersensitivity active substance ( fesoterodine ) peanut soya excipients , urinary retention , gastric retention . Patients significant hepatic renal disease significant unstable disease . OAB symptom cause neurological condition , know pathology urinary tract , etc .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>